Biomedical Research
Online ISSN : 1880-313X
Print ISSN : 0388-6107
Communication
ProGRP is a possible tumor marker for patients with Ewing sarcoma
Ken YAMAGUCHIHirohisa KATAGIRIMitsuru TAKAHASHIYuji ISHIDAAkira ONOToshiaki TAKAHASHIKeiichi OHSHIMATohru MOCHIZUKIKenichi URAKAMIKoji MURAMATSUToru KAMEYAIchiro ITOTakashi NAKAJIMA
Author information
JOURNALS FREE ACCESS

2015 Volume 36 Issue 4 Pages 273-277

Details
Abstract

We analyzed serum ProGRP levels in patients with Ewing sarcoma, and found that 5 out of 9 patients had elevated levels; the values range equally with those of patients with limited disease of small-cell lung carcinoma. Serum ProGRP levels in patients with bone and soft tissue malignancies other than Ewing sarcoma are not elevated. Immunohistochemical studies demonstrated that ProGRP-like immunoreactivities were detected in Ewing sarcoma tissues obtained from 2 patients with elevated serum ProGRP levels, suggesting that ProGRP is a product of tumor cells of Ewing sarcoma. These results indicate that serum ProGRP could serve as a specific tumor marker for Ewing sarcoma. Since ProGRP is a major hormonal product of tumor cells of small-cell lung carcinoma, a typical neuroendocrine carcinoma, it is reasonable to postulate that the present study provides an evidence for Ewing sarcoma to possess neuroendocrine differentiation.

Information related to the author
© 2015 Biomedical Research Press
Previous article
feedback
Top